Literature DB >> 24061908

Modeling potential time to event data with competing risks.

Liang Li1, Bo Hu, Michael W Kattan.   

Abstract

Patients receiving radical prostatectomy are at risk of metastasis or prostate cancer related death, and often need repeated clinical evaluations to determine whether additional adjuvant or salvage therapies are needed. Since the prostate cancer is a slowly progressing disease, and these additional therapies come with significant side effects, it is important for clinical decision making purposes to estimate a patient's risk of cancer metastasis, in the presence of a competing risk by death, under the hypothetical condition that the patient does not receive any additional therapy. In observational studies, patients may receive additional therapy by choice; the time to metastasis without any therapy is often a potential outcome and not always observed. We study the competing risks model of Fine and Gray (J Am Stat Assoc, 94:496-509, 1999) with adjustment for treatment choice by inverse probability censoring weighting (IPCW). The model can be fit using standard software for partial likelihood with double IPCW weights. The proposed methodology is used in a prostate cancer study to predict the post-prostatectomy cumulative incidence probability of cancer metastasis without additional adjuvant or salvage therapies.

Entities:  

Mesh:

Year:  2013        PMID: 24061908      PMCID: PMC4197853          DOI: 10.1007/s10985-013-9279-z

Source DB:  PubMed          Journal:  Lifetime Data Anal        ISSN: 1380-7870            Impact factor:   1.588


  19 in total

Review 1.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Authors:  T A Gooley; W Leisenring; J Crowley; B E Storer
Journal:  Stat Med       Date:  1999-03-30       Impact factor: 2.373

2.  Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests.

Authors:  J M Robins; D M Finkelstein
Journal:  Biometrics       Date:  2000-09       Impact factor: 2.571

3.  Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study.

Authors:  Jared K Lunceford; Marie Davidian
Journal:  Stat Med       Date:  2004-10-15       Impact factor: 2.373

4.  Sensitivity analyses for unmeasured confounding assuming a marginal structural model for repeated measures.

Authors:  Babette A Brumback; Miguel A Hernán; Sebastien J P A Haneuse; James M Robins
Journal:  Stat Med       Date:  2004-03-15       Impact factor: 2.373

5.  Assessment of endpoints for clinical trials for localized prostate cancer.

Authors:  P Schellhammer; A Cockett; L Boccon-Gibod; M Gospodarowicz; A Krongrad; I M Thompson; P Scardino; M Soloway; J Adolfsson
Journal:  Urology       Date:  1997-04       Impact factor: 2.649

6.  Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.

Authors:  Rebecca Siegel; Elizabeth Ward; Otis Brawley; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2011-06-17       Impact factor: 508.702

7.  Natural history of progression after PSA elevation following radical prostatectomy.

Authors:  C R Pound; A W Partin; M A Eisenberger; D W Chan; J D Pearson; P C Walsh
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

8.  20-year outcomes following conservative management of clinically localized prostate cancer.

Authors:  Peter C Albertsen; James A Hanley; Judith Fine
Journal:  JAMA       Date:  2005-05-04       Impact factor: 56.272

9.  A competing-risks nomogram for sarcoma-specific death following local recurrence.

Authors:  Michael W Kattan; Glenn Heller; Murray F Brennan
Journal:  Stat Med       Date:  2003-11-30       Impact factor: 2.373

10.  Competing risks and the clinical community: irrelevance or ignorance?

Authors:  Michael T Koller; Heike Raatz; Ewout W Steyerberg; Marcel Wolbers
Journal:  Stat Med       Date:  2011-09-23       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.